Pharmaceutical

ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention

Experts discuss the relationship between obesity and heart failure while referencing new clinical trial results.

Aug 31, 2024 - 04:00
ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention
Experts discuss the relationship between obesity and heart failure while referencing new clinical trial results.
Read the original article

Tags:

Previous Article

ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam

Next Article

Acute On Chronic Liver Failure (ACLF) drugs in development, 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Avalyn raises $175m in funding to develop inhaled IPF drugs

Avalyn raises $175m in funding to develop inhaled IPF d...

Sep 27, 2023

Chiesi partners with Haisco to commercialise bronchiectasis drug  

Chiesi partners with Haisco to commercialise bronchiect...

Nov 20, 2023

With latest tranche, U.K. Biobank has genome sequences from 500,000 people available for research

With latest tranche, U.K. Biobank has genome sequences ...

Nov 29, 2023